Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), is pleased to announce the appointment of Dr. Lilly Xu as its new Chief Technology Officer (CTO). Bringing over 30 years of extensive experience in early drug discovery and development, Dr. Xu will drive Medicilon’s technological innovation and international growth, further enhancing its capabilities to deliver cutting-edge R&D solutions.
Dr. Xu, who earned her Ph.D. in Biology from St. Louis University and was an early pioneer of human hepatocyte isolation, metabolism and DDI, is widely regarded as an expert in drug metabolism, pharmacokinetics, and exploratory toxicology. She has successfully led multiple global drug development programs from early discovery through clinical stages and held leadership roles at major pharmaceutical and biotechnology companies such as Amgen and Sanofi.
“We are delighted to welcome Dr. Xu at this pivotal moment in Medicilon’s expansion,” said Dr. Chunlin Chen, Founder and CEO of Medicilon. “Her deep expertise and global perspective align perfectly with our vision of driving innovation and accelerating our international growth.”
“I’m thrilled to join Medicilon’s forward-thinking team,” said Dr. Xu. “I look forward to supporting our global clients by leveraging Medicilon’s extensive preclinical resources, fostering platform innovation, and helping expedite the transition of groundbreaking research into clinical successes that ultimately benefit patients worldwide.”
Medicilon continues to strengthen its discovery research platforms - including chemistry, discovery biologics, and pharmacology - fortifying its position as a leader in preclinical drug discovery and development.
Website: https://www.medicilon.com/
SOURCE Medicilon Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article